Clinical Study on the Effect of Bifid Triple Viable in the Eradication Treatment of Helicobacter pylori_West China Medical Journal

Authors：

 ZhouHaijuan

Department of Internal Medicine, the Third People's Hospital of Yangzhou, Yangzhou, Jiangsu 225000, P. R. China;

Corresponding?author：

Keywords：

Bifid triple viable; Chronic gastritis; Helicobacter pylori; Infection

DOI：

10.7507/1002-0179.201600457

Video：

Export PDF Favorites Scan Get Citation

Abstract Full text Figures/Tables Video References Cited by

Objective To investigate the effect of sequential use of bifid triple viable in the eradication treatment of Helicobacter pylori (HP). Methods A total of 183 HP positive chronic gastritis patients with gastric mucosa atrophy or erosion treated between October 2012 and October 2014 were randomly divided into three groups with 61 in each. The triple group received standard one-week triple therapy. The quadruple group received standard two-week quadruple therapy. The bifid triple viable group was given one week of standard quadruple therapy and one week of sequential bifid triple viable. One month after withdrawal of the medicine, HP eradication rate, clinical efficacy and adverse reactions were compared among the three groups. Results The HP eradication rate in the triple group was 72.13%, significantly lower than that in the quadruple group (93.44%) and in the bifid triple viable group (90.16%) (P < 0.05). The HP eradication rate in the bifid triple viable group was slightly lower than that in the quadruple group (P > 0.05). The total effective rate in the quadruple group and bifid triple viable group was respectively 95.08% and 91.80%, with no significant difference between the two groups (P > 0.05), but they both were significantly higher than that in the bifid triple viable group (P < 0.05). Eleven cases of adverse reactions happened during the process of eradication treatment of HP. The adverse reactions were not serious, and could be solved with symptomatic treatments. The adverse reaction rate in the quadruple group was significantly higher than that in the bifid triple viable group (P < 0.05). Conclusion Sequential use of bifid triple viable capsule can improve the rate of HP eradication, relieve the clinical symptoms effectively, reduce adverse reactions, and reduce the medical cost.

Citation： ZhouHaijuan. Clinical Study on the Effect of Bifid Triple Viable in the Eradication Treatment of Helicobacter pylori. West China Medical Journal, 2016, 31(10): 1663-1666. doi: 10.7507/1002-0179.201600457 Copy

1.	Correa P, Houghton JM. Carcinogenesis of Helicobacter pylori[J]. Gastroenterology, 2007, 133(2): 659-672.
2.	中華醫學會消化病學分會幽門螺桿菌學組/全國幽門螺桿菌研究協作組, 劉文忠, 謝勇, 等.第四次全國幽門螺桿菌感染處理共識報告[J].中華消化雜志, 2012, 32(10): 655-661.
3.	Rokkas T, Pistiolas D, Sechopoulos PA, et al. The long-term impact of Helicobacter pylori eradication on gastric histology: a systematic review and meta-analysis[J]. Helicobacter, 2007, 12(2): 32-38.
4.	Wang J, Xu LJ, Shi RH, et al. Gastric atrophy and intestinal metaplasia before and after Helicobacter pylori eradication: a Meta-analysis[J]. Digestion, 2011, 83(4): 253-260.
5.	張萬岱, 胡伏蓮, 蕭樹東, 等.中國自然人群幽門螺桿菌感染的流行病學調查[J].現代消化及介入診療, 2010, 15(5): 265-270.
6.	Yan X, Zhou L, Song Z, et al. Seguential therapy for Helicobacter pylori eradication in adults compared with triple therapy in China: a multiplecenter, prosepectice, randomized, controlled trial (abstract) [J]. Helicobacter, 2011, 16(Suppl 1): 87.
7.	Malfertheiner P, Bazzoli F, Delchier JC, et al. Helicobacter pylori eradication with a capsule containing bismuth subcitrate potassium, metronidazole, and tetracycline given with omeprazole versus clarithromycin-based triple therapy: a randomized, openlabel non-inferiority, phase 3 trial[J]. Lancet, 2011(377): 905-913.
8.	牟方宏, 胡伏蓮, 楊佳彬, 等.質子泵抑制劑四聯療法作為幽門螺桿菌根除治療一線方案的臨床研究[J].胃腸病學, 2007, 12(9): 531-534.
9.	王瑋, 王釗, 張露.消化道疾病患者幽門螺桿菌感染與治療分析[J].中華醫院感染學雜志, 2014, 24(24): 6147-6148.
10.	Sheu BS, Yang HB, Wang YL, et al. Pretreatment gastric histology is helpful to predict the symptomatic response after H.pylori eradication in patients with nonucler despepsia[J]. Dig Dis Sci, 2001, 46(12): 2700-2707.
11.	Zhou LY, Sung JJ, Lin SR, et al. A five-year follow-up study on the pathological changes of gastric mucosa after H-pylori eradication[J]. Chin Med J (Engl), 2003, 116(1): 11-14.
12.	Wang ZH, Gao QY, Fang JY. Meta-analysis of the efficacy and safety of Lactobacillus-containing and Bifidobacterium-containing probiotic compound preparation in Helicobacter pylori eradication therapy[J]. J Clin Gastroenterol, 2013, 47(1): 25-32.
13.	黎莉, 楊衛文, 楊景林, 等.含益生菌四聯療法根治頑固性幽門螺桿菌感染的療效觀察[J].中國微生態學雜志, 2013, 25(6): 673-675.
14.	凌云.益生菌應用在感染幽門螺桿菌消化性潰瘍治療中的作用[J].世界華人消化雜志, 2014, 22(33): 5203-5206.
15.	Du YQ, Su T, Fan JG, et al. Adjuvant probiotics improve the eradication effect of triple therapy for Helicobacter pylori infection[J]. World J Gastroenterol, 2012, 18(43): 6302-6307.
16.	何晨熙, 劉改芳.益生菌在根除幽門螺桿菌治療中的作用[J].胃腸病學和肝病學雜志, 2014, 23(7): 839-842.

1. Correa P, Houghton JM. Carcinogenesis of Helicobacter pylori[J]. Gastroenterology, 2007, 133(2): 659-672.
2. 中華醫學會消化病學分會幽門螺桿菌學組/全國幽門螺桿菌研究協作組, 劉文忠, 謝勇, 等.第四次全國幽門螺桿菌感染處理共識報告[J].中華消化雜志, 2012, 32(10): 655-661.
3. Rokkas T, Pistiolas D, Sechopoulos PA, et al. The long-term impact of Helicobacter pylori eradication on gastric histology: a systematic review and meta-analysis[J]. Helicobacter, 2007, 12(2): 32-38.
4. Wang J, Xu LJ, Shi RH, et al. Gastric atrophy and intestinal metaplasia before and after Helicobacter pylori eradication: a Meta-analysis[J]. Digestion, 2011, 83(4): 253-260.
5. 張萬岱, 胡伏蓮, 蕭樹東, 等.中國自然人群幽門螺桿菌感染的流行病學調查[J].現代消化及介入診療, 2010, 15(5): 265-270.
6. Yan X, Zhou L, Song Z, et al. Seguential therapy for Helicobacter pylori eradication in adults compared with triple therapy in China: a multiplecenter, prosepectice, randomized, controlled trial (abstract) [J]. Helicobacter, 2011, 16(Suppl 1): 87.
7. Malfertheiner P, Bazzoli F, Delchier JC, et al. Helicobacter pylori eradication with a capsule containing bismuth subcitrate potassium, metronidazole, and tetracycline given with omeprazole versus clarithromycin-based triple therapy: a randomized, openlabel non-inferiority, phase 3 trial[J]. Lancet, 2011(377): 905-913.
8. 牟方宏, 胡伏蓮, 楊佳彬, 等.質子泵抑制劑四聯療法作為幽門螺桿菌根除治療一線方案的臨床研究[J].胃腸病學, 2007, 12(9): 531-534.
9. 王瑋, 王釗, 張露.消化道疾病患者幽門螺桿菌感染與治療分析[J].中華醫院感染學雜志, 2014, 24(24): 6147-6148.
10. Sheu BS, Yang HB, Wang YL, et al. Pretreatment gastric histology is helpful to predict the symptomatic response after H.pylori eradication in patients with nonucler despepsia[J]. Dig Dis Sci, 2001, 46(12): 2700-2707.
11. Zhou LY, Sung JJ, Lin SR, et al. A five-year follow-up study on the pathological changes of gastric mucosa after H-pylori eradication[J]. Chin Med J (Engl), 2003, 116(1): 11-14.
12. Wang ZH, Gao QY, Fang JY. Meta-analysis of the efficacy and safety of Lactobacillus-containing and Bifidobacterium-containing probiotic compound preparation in Helicobacter pylori eradication therapy[J]. J Clin Gastroenterol, 2013, 47(1): 25-32.
13. 黎莉, 楊衛文, 楊景林, 等.含益生菌四聯療法根治頑固性幽門螺桿菌感染的療效觀察[J].中國微生態學雜志, 2013, 25(6): 673-675.
14. 凌云.益生菌應用在感染幽門螺桿菌消化性潰瘍治療中的作用[J].世界華人消化雜志, 2014, 22(33): 5203-5206.
15. Du YQ, Su T, Fan JG, et al. Adjuvant probiotics improve the eradication effect of triple therapy for Helicobacter pylori infection[J]. World J Gastroenterol, 2012, 18(43): 6302-6307.
16. 何晨熙, 劉改芳.益生菌在根除幽門螺桿菌治療中的作用[J].胃腸病學和肝病學雜志, 2014, 23(7): 839-842.

West China Medical Journal

Clinical Study on the Effect of Bifid Triple Viable in the Eradication Treatment of Helicobacter pylori

Abstract Full text Figures/Tables Video References Cited by

Previous Article

Next Article

Format

Content